Scinai Immunotherapeutics (SCNI)

• Market cap: $2.43M
• 1 day: -4.36%
• 5 days: -14.41%
• 1 month: -24.00%
• 3 months: -24.40%
• 6 months: -35.23%
• Year to date: -53.28%
• 1 year: -56.75%
• 5 years: -99.51%
• 10 years: -99.29%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

Employees: 31

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% less ownership

Funds ownership: 0% [Q2] → 0% (-0%) [Q3]

44% less funds holding

Funds holding: 9 [Q2] → 5 (-4) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

87% less capital invested

Capital invested by funds: $55.4K [Q2] → $7.09K (-$48.3K) [Q3]

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4